Loading patent…
AssigneeRamot at Tel-Aviv University Ltd.
InventorsBeka Solomon, Noa Sharon, Oded Grinstein
Estimating the term…
A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar inclusions or aggregates. Filamentous bacteriophage which displays a non-filamentous bacteriophage RGD cell adhesion sequence on its surface, but not an antibody or non-filamentous bacteriophage antigen other than said RGD cell adhesion sequence, is a preferred embodiment of such a therapeutic agent.
A method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates, comprising administering to a mammalian subject in need thereof an effective amount of a therapeutic agent which carries a peptide sequence comprising a mammalian cell adhesion sequence, wherein the therapeutic agent is one which inhibits the intracellular formation of protein fibrillar inclusions or aggregates or which disaggregates pre-formed intracellular protein fibrillar inclusions or aggregates and the mammalian cell adhesion sequence is displayed so as to be capable of causing internalization of said therapeutic agent into cells to inhibit or treat the disease.
14-17. (canceled)
A method for inhibiting the intracellular formation of protein fibrillar inclusions or aggregates, comprising causing a therapeutic agent, which carries a peptide sequence comprising a mammalian cell adhesion sequence, wherein the therapeutic agent is one which inhibits the intracellular formation of protein fibrillar inclusions or aggregates or which disaggregates pre-formed intracellular protein fibrillar inclusions or aggregates and the mammalian cell adhesion sequence is displayed so as to be capable of causing internalization of said therapeutic agent into mammalian cells, to be in contact with an intracellular peptide or polypeptide capable of forming protein fibrillar inclusions or aggregates to inhibit the intracellular formation of protein fibrillar inclusions or aggregates.
20-28. (canceled)
A method for disaggregating pre-formed intracellular protein fibrillar inclusions or aggregates, comprising causing a therapeutic agent, which carries a peptide sequence comprising a mammalian cell adhesion sequence, wherein the therapeutic agent is one which inhibits the intracellular formation of protein fibrillar inclusions or aggregates or which disaggregates pre-formed intracellular protein fibrillar inclusions or aggregates and the mammalian cell adhesion sequence is displayed so as to be capable of causing internalization of said therapeutic agent into cells, to be in contact with pre-formed intracellular protein fibrillar inclusions or aggregates to disaggregate the pre-formed intracellular protein fibrillar inclusions or aggregates.
31-39. (canceled)
A pharmaceutical composition, comprising a pharmaceutically acceptable carrier or excipient and, as an active ingredient, an effective amount of a therapeutic agent which carries a peptide sequence comprising a mammalian cell adhesion sequence, wherein the therapeutic agent is one which inhibits the intracellular formation of protein fibrillar inclusions or aggregates or which disaggregates pre-formed intracellular protein fibrillar inclusions or aggregates and the mammalian cell adhesion sequence is displayed so as to be capable of causing internalization of said therapeutic agent into cells.
51-60. (canceled)
Dependencies are inferred from the claim text.